SS-31 (Elamipretide): Research Peptide Product Information

Product Overview

SS-31 (Elamipretide) is a synthetic mitochondria-targeting tetrapeptide investigated for its interactions with cardiolipin, a phospholipid found in the inner mitochondrial membrane. Scientific interest in elamipretide centers on mitochondrial structure, cellular bioenergetics, and mechanisms involved in energy production.

Unlike many peptides studied primarily in preclinical models, elamipretide has also been evaluated in human clinical trials for specific medical conditions. In the United States, an authorized prescription formulation, Forzinity, received accelerated FDA approval in 2025 for improving muscle strength in patients with Barth syndrome who meet the labeled age and weight criteria. That specific approval should not be generalized to other formulations or uses.

This page provides scientific and product information for research contexts. The product name alone does not establish its formulation, quality, regulatory status, or suitability for any particular application.

What Is SS-31 (Elamipretide)?

SS-31 is a synthetic tetrapeptide also known in scientific literature as elamipretide, MTP-131, and Bendavia. It is designed to target mitochondria, the cellular structures responsible for many essential processes involved in energy metabolism.

Elamipretide is notable for its interaction with cardiolipin, a lipid that contributes to the organization and function of the inner mitochondrial membrane. This interaction has made the peptide a subject of research into mitochondrial membrane structure, electron transport, and cellular energy processes.

Although the names SS-31 and elamipretide are commonly associated with the same active peptide, a research product bearing either name should not automatically be considered equivalent to an authorized pharmaceutical formulation. Chemical identity, salt form, purity, formulation, manufacturing controls, and applicable authorization all matter when evaluating a specific product.

How Does Elamipretide Work?

Interaction With Cardiolipin

Cardiolipin is a specialized phospholipid concentrated in the inner mitochondrial membrane. It helps organize membrane structure and supports the function of proteins involved in mitochondrial energy metabolism.

Elamipretide has been studied for its ability to bind cardiolipin and influence the organization of mitochondrial membrane structures. Researchers are investigating how this interaction may affect the stability of mitochondrial cristae and the organization of components involved in cellular respiration.

These mechanisms are scientifically relevant, but molecular interaction alone does not establish a clinical benefit. The effects observed in a particular experimental model may not translate into measurable improvements in human health.

Mitochondrial Bioenergetics

Mitochondria contribute to the production of adenosine triphosphate (ATP), which supplies energy for many cellular processes. Research has examined whether elamipretide can influence mitochondrial respiration, energy production, and related biochemical measurements under specific experimental conditions.

Studies have explored these effects in laboratory systems, animal models, and human participants. Results vary by population, disease, treatment setting, and endpoint, so findings from one study should not be generalized to every condition or to healthy individuals.

Oxidative Stress and Cellular Function

Elamipretide has also been investigated in relation to oxidative processes and the function of proteins associated with mitochondrial membranes. These investigations help researchers understand how changes in mitochondrial structure may influence cellular physiology.

It would be inaccurate, however, to describe SS-31 as a proven anti-aging treatment, universal mitochondrial enhancer, or established means of increasing energy in healthy people. Those claims require direct clinical evidence for the specific use being advertised.

Research and Clinical Evidence

Elamipretide has been investigated in several research areas, including mitochondrial disorders, cardiovascular conditions, skeletal muscle function, and age-related changes in mitochondrial physiology.

Its evidence base includes both preclinical studies and human clinical trials. The clinical findings are condition-specific, and outcomes have not been uniformly positive across all investigational uses.

For example, a randomized, placebo-controlled study involving 39 older adults examined mitochondrial energetic measurements following a single exposure to elamipretide. The researchers reported findings suggesting a possible effect on certain energetic measurements, but the study was small and does not establish long-term health benefits or support general wellness claims.

Research in primary mitochondrial myopathy has also produced mixed results. A large controlled trial did not demonstrate a significant benefit on its primary endpoint, illustrating why promising mechanisms and early-stage findings must be distinguished from demonstrated clinical effectiveness.

FDA Approval for a Specific Medical Indication

In September 2025, the U.S. FDA granted accelerated approval to Forzinity, an elamipretide injection, to improve muscle strength in adult and pediatric patients with Barth syndrome who weigh at least 30 kg.

This is a meaningful regulatory milestone, but its scope is specific:

It applies to the authorized Forzinity prescription product.
It applies to the labeled indication and eligible patient population.
The approval was based on an intermediate clinical endpoint under the accelerated approval pathway.
Continued approval may depend on confirmation of clinical benefit in required follow-up studies.

This authorization does not establish that all SS-31 products are interchangeable with Forzinity, nor does it approve general use for longevity, exercise performance, fatigue, healthy aging, or unrelated mitochondrial conditions.

Product Identity and Composition

This listing is identified as SS-31 (Elamipretide). No product strength, salt form, or formulation has been specified in the supplied product name, so those details should be verified against the actual label and supporting documentation.

When evaluating a product identified as SS-31, relevant information may include:

Verified molecular identity and peptide sequence.
Stated quantity and chemical form.
Batch or lot number.
Identity and purity testing methods.
Relevant impurity and degradation information.
Formulation and product-specific stability data.
Traceability and supporting quality documentation.

A matching name alone does not prove that a research product has the same formulation, manufacturing quality, or regulatory status as an authorized prescription medicine.

Quality, Testing, and Documentation

Transparent product documentation is important for scientific reproducibility and meaningful product evaluation. Where available and verifiable, relevant records may include:

A batch-specific certificate of analysis (COA).
Peptide identity confirmation.
Reported purity and the analytical method used.
Information about relevant impurities and degradation products.
Batch identification and traceability.
Product-specific storage and stability information.

A purity percentage alone does not establish sterility, endotoxin control, long-term stability, pharmaceutical manufacturing compliance, or suitability for human administration. Likewise, the existence of a COA does not automatically mean that a product is equivalent to an approved pharmaceutical.

Peptika should make claims such as “HPLC-tested,” “independently tested,” or “COA available” only when they are supported by actual documentation applicable to the specific product and batch.

Safety and Regulatory Considerations

Elamipretide’s clinical evidence and regulatory status depend on the specific product, condition, population, and jurisdiction. The FDA authorization of Forzinity should not be interpreted as blanket approval for all products sold under the names SS-31, MTP-131, or elamipretide.

Unapproved or research-market products may differ from authorized medicines in formulation, quality controls, manufacturing, and labeling. Product availability does not independently establish safety or suitability for human use.

This page is not a substitute for an authorized medicine’s prescribing information, professional medical advice, or applicable regulatory requirements. No dosing, preparation, or administration recommendation is provided here.

Researchers and commercial sellers should accurately distinguish a research-designated material from an authorized prescription product and ensure that product claims comply with applicable laws and marketplace requirements.

Frequently Asked Questions

What is SS-31 (Elamipretide)?

SS-31, commonly known as elamipretide, is a synthetic mitochondria-targeting tetrapeptide studied for its interaction with cardiolipin and its potential effects on mitochondrial structure and bioenergetics.

What is the difference between SS-31 and elamipretide?

SS-31 is a widely used research name for the peptide also called elamipretide. Other names in the scientific literature include MTP-131 and Bendavia. Nevertheless, product identity and equivalence should be verified through documentation rather than inferred from a name alone.

What is elamipretide being researched for?

Research has examined mitochondrial biology, cellular energy processes, certain mitochondrial disorders, cardiovascular conditions, and skeletal muscle function. Evidence and outcomes differ by indication, and not every investigational use has demonstrated clinical effectiveness.

Is SS-31 FDA-approved?

The FDA granted accelerated approval to Forzinity (elamipretide) injection in September 2025 for improving muscle strength in adults and children weighing at least 30 kg with Barth syndrome. That approval is specific to the authorized prescription product and labeled indication; it does not mean every product sold as SS-31 is FDA-approved.

Does FDA approval mean all SS-31 products are equivalent to Forzinity?

No. Approval applies to a particular drug product, formulation, manufacturing controls, and labeled use. A research-market product cannot be presumed equivalent based solely on its name or stated peptide content.

Does SS-31 improve mitochondrial function in healthy people?

Some studies have investigated mitochondrial measurements in healthy older adults, but limited findings from individual studies do not establish a general or sustained health benefit. Evidence does not support presenting SS-31 as a proven wellness, longevity, or performance-enhancement product.

What documentation should be reviewed for a research product?

Where available, relevant documentation includes batch-specific identity and purity results, impurity information, a COA, traceability, and product-specific stability information. Such documents should be reviewed for their methods and scope and should not be treated as proof of pharmaceutical equivalence or clinical suitability.

Is SS-31 a proven anti-aging treatment?

No. Although mitochondrial biology is relevant to aging research, the available evidence does not establish SS-31 as a proven treatment for aging or as a means of extending lifespan in humans.

Conclusion

SS-31 (elamipretide) is a mitochondria-targeting tetrapeptide with a distinctive research history involving cardiolipin and mitochondrial bioenergetics. Its development includes preclinical investigations, human clinical trials, and a specific FDA-approved prescription application for Barth syndrome.

For Peptika, the most credible product page is one that explains the science, accurately distinguishes research products from authorized medicines, and presents quality documentation without overstating clinical benefits. Clear product identification and evidence-based language help customers understand what the listing does—and does not—establish.

Research-Use Disclaimer

This page is provided for scientific and educational context only. It is not medical advice, a diagnosis, or a recommendation for human or veterinary use. The existence of an authorized elamipretide medicine for a specific indication does not establish that this listed product is approved, equivalent, clinically effective, or suitable for administration. Product strength, formulation, quality, and testing claims should be verified against the actual label and supporting documentation. Users and sellers are responsible for complying with applicable laws, institutional requirements, and relevant regulatory guidance.

elamipretide regulatory status

SS-31 (Elamipretide)